Twist Bioscience Corporation

Biological Products, (No Diagnostic Substances)

TWSTStrong5 of 9 basics passed

$161.77

+6.39%

Market cap $10.7B

$161.77

+6.39%

Market cap $10.7B

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

It is a $10.7B healthcare company. Revenue grew 19.2% over the last year, and it currently loses money.

Website: twistbioscience.com
Location: South San Francisco, CA
Employees: 979
Sector: Healthcare
Founded: 2013

Share price · 3 years

$19.41 → $161.77+733.4%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $432M
Loss: spends more than it earns; -$137M
Free cash flow: cash left after running the business; -$93.1M
Shares: up 11% since 2022 — dilution; 59.8M
Volatility: beta vs the market — under 1 swings less; 2.15

Revenue, last 7 years

52-week range

Low $25.45$161.77High $205.00

Today's price is 76% of the way from the year's low to its high.

Valuation vs own history

P/S

24.5×

P/B

23.8×

Share of the last ~5 years that was pricier than today (unusually expensive vs its own history). Based on the daily valuation record.

Insider activity · 90 days

-$20.1Mnet selling

Purchases$0

Sales$20.1M

Insiders trading, last 14d0 buy · 6 sell

Standing in Healthcare

Size$10.7Btop 82%
Revenue growth+23%top 16%
Net margin-32%top 86%
Return on equity-30%top 87%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Valuation, Growth, Profitability, Quality and Moat lag behind.

Valuation20

P/E vs own historyn/a · 10/25
FCF yield-0.9% · 0/25
P/S24.4x · 0/25
EV/EBITDAn/a · 10/25

Growth25

Revenue CAGR29.9% · 25/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROIC-32.3% · 0/25
ROE-29.9% · 0/25
Net margin-31.7% · 0/25
Operating margin-33.6% · 0/25

Health50

Altman Z24.18 · 25/25
Current ratio2.67 · 25/25
Interest coverage-235.7x · 0/25
Net cash / debtn/a · 0/25

Quality35

Piotroski F4/9 · 10/25
Beneish M-2.67 · 25/25
FCF conversionn/a · 0/25
Margin stabilityσ 70.0% · 0/25

Moat13

ROIC >12% years0/7 yrs · 0/25
Median gross margin39.1% · 13/25
FCF-positive years0/7 yrs · 0/25
Worst-year net marginworst -198.0% · 0/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

2021Product
Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design
2013Founded
Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$14 684 today — price return only

$376.6M revenue in FY2025

Revenue up 19.2% year over year

979 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (52.0%)
Revenue growing 19.2% year over year
Altman Z-Score 24.18 — low bankruptcy-risk zone

Watch-outs

Not profitable — 31.7% net margin
Negative free cash flow (-$93.1M)
Thin interest coverage (-235.7×)
Loss-making in 7 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

5 of 9 checks passed

Revenue growing — the company sells more than a year ago+19.2% YoY
Profitable — makes more than it spends-$137M TTM
Profit growing — earnings are higher than last year+62.8% YoY
Generates cash — cash left after running and investing-$93.1M TTM
Debt under control — could handle its obligationscurrent ratio 2.67
Established company — not a micro-cap — lower blow-up risk$10.7B market cap
Not printing shares — share count not ballooning — you keep your slice+11.0% shares over ~5y
Proven track record — years of profitability behind it0/7 profitable years
Financially stable — balance sheet not near distressAltman Z 24.2 — safe
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparisonTwist Bioscience Corporation vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
TWST this company	$10.7B	—	+19.2%	-31.7%	Strong
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: TWST vs LLY · TWST vs JNJ · TWST vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 7Buy 7Hold 2

Appendix · Financial records

The full statements behind this CV, FY2019–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $432M · net income -$137M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$432M

YoY 19.2%

Net income (TTM)

-$137M

Margin -31.7%

Gross margin

52.0%

Operating margin

-33.6%

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.1	0.1	0.2	0.2	0.3	0.4
Gross profit	0.0	0.1	0.1	0.1	0.1	0.2
Operating income (EBIT)	-0.1	-0.2	-0.2	-0.2	-0.2	-0.1
Net income	-0.1	-0.2	-0.2	-0.2	-0.2	-0.1
EPS (diluted)	—	—	-4.04	-3.60	-3.60	-1.30

Cash flowFree cash flow -$93.1M · operating cash flow -$53.1M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

-$93.1M

Margin -21.6%

Operating cash flow (TTM)

-$53.1M

FCF margin

-21.6%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	-0.1	-0.1	-0.1	-0.1	-0.1	-0.0
Capital expenditure	-0.0	-0.0	-0.1	-0.0	-0.0	-0.0
Free cash flow	-0.2	-0.1	-0.2	-0.2	-0.1	-0.1
FCF margin	-168.8%	-105.3%	-111.1%	-69.5%	-22.1%	-20.1%

Balance sheetAssets $642M · debt n/a (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $642M of assets is financed

26%

74%

Liabilities $169M — borrowed moneyEquity $473M — owners' stake

Altman Z-Score

24.18

Safe zone

Debt repayment

0.0 yrs

Years of free cash flow to clear net debt

Interest coverage

-235.7x

EBIT ÷ interest expense

ROE

-29.9%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.3	0.5	0.5	0.3	0.3	0.2
Total assets	0.4	0.7	1.0	0.8	0.6	0.6
Total liabilities	0.1	0.1	0.2	0.2	0.1	0.2
Total debt	0.0	—	—	—	—	—
Equity	0.3	0.6	0.8	0.6	0.5	0.5
Net debt	-0.3	—	—	—	—	—

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of TWST on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $161.77 · market cap $10.7B.